[go: up one dir, main page]

MX2019005684A - Métodos para detectar mutaciones de fibrosis quística mediante el uso de extracción con puntas mitra. - Google Patents

Métodos para detectar mutaciones de fibrosis quística mediante el uso de extracción con puntas mitra.

Info

Publication number
MX2019005684A
MX2019005684A MX2019005684A MX2019005684A MX2019005684A MX 2019005684 A MX2019005684 A MX 2019005684A MX 2019005684 A MX2019005684 A MX 2019005684A MX 2019005684 A MX2019005684 A MX 2019005684A MX 2019005684 A MX2019005684 A MX 2019005684A
Authority
MX
Mexico
Prior art keywords
cystic fibrosis
methods
tip extraction
fibrosis mutations
detecting
Prior art date
Application number
MX2019005684A
Other languages
English (en)
Inventor
J Clarke Nigel
SANDERS Heather
Original Assignee
Quest Diagnostics Invest Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Diagnostics Invest Llc filed Critical Quest Diagnostics Invest Llc
Publication of MX2019005684A publication Critical patent/MX2019005684A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación proporciona métodos para determinar si un paciente que muestra síntomas de fibrosis quística, o un paciente en riesgo de padecer fibrosis quística, se podría beneficiar del tratamiento con uno o más agentes terapéuticos anti fibrosis quística. Estos métodos se basan en detectar mutaciones relacionadas a la fibrosis quística hereditaria en muestras de fluidos biológicos secos de volumen pequeño, las cuales son recolectadas utilizando un dispositivo volumétrico absortivo de micromuestreo. Los kits para usarse en la práctica de los métodos también son proporcionados.
MX2019005684A 2016-11-15 2017-11-13 Métodos para detectar mutaciones de fibrosis quística mediante el uso de extracción con puntas mitra. MX2019005684A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662422338P 2016-11-15 2016-11-15
PCT/US2017/061311 WO2018093723A1 (en) 2016-11-15 2017-11-13 Methods for detecting cystic fibrosis mutations using mitra tip extraction

Publications (1)

Publication Number Publication Date
MX2019005684A true MX2019005684A (es) 2019-10-30

Family

ID=62106739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005684A MX2019005684A (es) 2016-11-15 2017-11-13 Métodos para detectar mutaciones de fibrosis quística mediante el uso de extracción con puntas mitra.

Country Status (8)

Country Link
US (3) US11486005B2 (es)
EP (1) EP3541953A4 (es)
JP (2) JP2020501601A (es)
CN (1) CN110168100A (es)
BR (1) BR112019009790A2 (es)
CA (1) CA3044033A1 (es)
MX (1) MX2019005684A (es)
WO (1) WO2018093723A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10656059B2 (en) 2018-03-07 2020-05-19 Alcala Pharmaceutical, Inc. Method for qualitative and quantitative multiplexing of drug analytes from biological samples
MX2021002122A (es) * 2018-08-22 2021-09-23 Quest Diagnostics Invest Llc Deteccion por micromuestreo en diabetes.
US11162921B2 (en) 2019-04-01 2021-11-02 Alcala Pharmaceutical, Inc. Method for extracting pharmacogenetic DNA from biological fluid retained in a solid resin collection device
WO2021091590A1 (en) * 2019-11-08 2021-05-14 Tissue Regeneration Technologies, Llc A method of treating the lungs

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5840702A (en) 1996-03-22 1998-11-24 Uab Research Foundation Cystic fibrosis treatment
US20040009924A1 (en) 1997-05-30 2004-01-15 Veronique Stoven Anticancer products for treating cystic fibrosis
AR033448A1 (es) 2001-03-28 2003-12-17 Ortho Clinical Diagnostics Inc Prueba de combinacion antigeno-anticuerpo para hepatitis c para una deteccion temprana de la infeccion
WO2006137733A1 (en) 2005-06-23 2006-12-28 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
US7838646B2 (en) 2005-08-18 2010-11-23 Quest Diagnostics Investments Incorporated Cystic fibrosis transmembrane conductance regulator gene mutations
US8962293B2 (en) 2006-10-18 2015-02-24 Roche Molecular Systems, Inc. DNA polymerases and related methods
ES2533861T3 (es) 2009-01-07 2015-04-15 Arcedi Biotech Aps Enriquecimiento e identificación de células fetales en sangre materna y ligandos para tal uso
FI3425062T3 (fi) 2010-06-09 2023-09-01 Keygene Nv Kombinatorisia sekvenssiviivakoodeja suuren suorituskyvyn seulontaa varten
EP2599877B1 (en) * 2010-06-30 2017-09-27 BGI Genomics Co., Limited New pcr sequencing method and use thereof in hla genotyping
US20130116597A1 (en) * 2011-11-04 2013-05-09 Phenomenex, Inc. Method and apparatus for acquiring blood for testing
US20160068906A1 (en) 2014-09-08 2016-03-10 Baby Genes, Inc. Method of screening newborns for gene variants
US20160281166A1 (en) 2015-03-23 2016-09-29 Parabase Genomics, Inc. Methods and systems for screening diseases in subjects
BR112019009798A2 (pt) 2016-11-15 2019-08-06 Quest Diagnostics Invest Llc método e kit para detectar vírus da hepatite c em uma amostra de fluido biológico secada, e, método para selecionar um paciente apresentando sintomas de hepatite.

Also Published As

Publication number Publication date
JP2022137019A (ja) 2022-09-21
US11473144B2 (en) 2022-10-18
EP3541953A4 (en) 2020-04-29
US20200056240A1 (en) 2020-02-20
WO2018093723A1 (en) 2018-05-24
US20230134138A1 (en) 2023-05-04
JP2020501601A (ja) 2020-01-23
EP3541953A1 (en) 2019-09-25
CN110168100A (zh) 2019-08-23
BR112019009790A2 (pt) 2019-08-06
US20180135128A1 (en) 2018-05-17
US11486005B2 (en) 2022-11-01
CA3044033A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
MX2019005683A (es) Metodos para detectar mutaciones de adn mediante el uso de extraccion con puntas mitra.
EP4190237A4 (en) DEVICE FOR DETECTING ANALYTES OF BODY FLUIDS
MX2019002471A (es) Sonda de recolección y métodos para su uso.
IL258101A (en) Device and system for testing samples, especially blood, and methods for using them
EP3353735A4 (en) METHOD AND DEVICES FOR FACILITATING END-USER DEFINED DIRECTIVE MANAGEMENT
PL4233721T3 (pl) Urządzenie medyczne do wykrywania co najmniej jednego analitu w płynie ustrojowym
LT4241683T (lt) Medicinos prietaisas, skirtas bent vienai analitei kūno skystyje aptikti
EP3490512A4 (en) DEVICE AND METHOD FOR RECEIVING EXHAUSTED URINE
EP3435760A4 (en) Apparatus and methods for sampling
MX2015017807A (es) Sistema cerrado integrado de extraccion de linea intravenosa.
MX2019005684A (es) Métodos para detectar mutaciones de fibrosis quística mediante el uso de extracción con puntas mitra.
DK3302235T3 (da) Anordning til diagnose af effektiviteten af en patients ventilation samt proces for bestemmelse af en patients ventilationseffektivitet
EP3305156A4 (en) DUST CONTAINER FOR VACUUM CLEANERS AND VACUUM CLEANERS
FR3016797B1 (fr) Dispositif motorise de musculation agoniste/antagoniste en contractions : excentrique, isometrique et concentrique, reactif a l'effort de l'utilisateur
EP3598104A4 (en) ANALYSIS DEVICE, ANALYSIS KIT, AND ANALYSIS SYSTEM
SG11202008891RA (en) Biological tissue analyzing device, biological tissue analyzing program, and biological tissue analyzing method
WO2018045208A8 (en) Collection probe and methods for the use thereof
IL276971A (en) In vitro device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof
EP3304028A4 (en) SAMPLING DEVICE
FR3032287B1 (fr) Dispositif de detection capacitif multicouches, et appareil comprenant le dispositif
MX2019005682A (es) Metodos y dispositivos para la deteccion del virus de la hepatitis c.
DK3161165T3 (da) Fremgangsmåde til diagnosticering af subklinisk og klinisk akut afstødning ved analyse af prædiktive gensæt, terapeutisk middel til anvendelse ved behandlingen og kits til at bestemme ekspressionen
EP3967229A4 (en) BLOOD COLLECTION TUBE HOLDER AND BLOOD COLLECTION KIT
SG11202110642VA (en) Method and device for measuring the fibrinogen concentration in blood samples.
EP3366364A4 (en) ABSORPTION LIQUID TO CO2 AND / OR H2S AND DEVICE AND METHOD FOR USE THEREOF